Scientists from UC Davis Center for Surgical Bioengineering, the MIND Institute and UC Berkeley’s Murthy Lab are developing ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...
As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...
KJ Muldoon, the first infant to undergo gene-editing therapy, has accomplished another first as a 1-year-old — his first steps KJ is walking at home ahead of Christmas after being hospitalized last ...
On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ), scooping up 145,153 shares in the gene-editing play.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback